Orizuru Therapeutics, Inc. is a clinical-stage biotech company developing first-in-class cell therapy products, differentiated from iPS cells, named OZTx-410 and OZTx-556, for the treatment of heart failure and Type 1 diabetes. OZTx-410 aims to provide ne